The sea anemone Stichodactyla helianthus, which carpets the Caribbean seafloor, may hold the key to eliminating the senescent cells that survive cancer therapy. A collaboration led by Spanish ...

Fannin Partners LLC has been awarded a $300,000 phase I Small Business Innovation Research (SBIR) grant from the National Eye ...

Disruption of alternative splicing can generate abnormal mRNA variants, producing nonfunctional proteins or triggering ...

Cellbxhealth plc, previously called Angle plc, appointed CEO Peter Collins along with several non-executives to its board as ...

Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process ...

The treatment of Pseudomonas aeruginosa infections is significantly challenged by the pathogen’s diverse resistance ...

Edwards Lifesciences Corp. said it is scrapping plans to acquire Jenavalve Technology Inc. for $945 million after a federal ...

Stoke Therapeutics Inc.’s speeded-up timeline for zorevunersen, the antisense oligonucleotide in development with Biogen Inc.

After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its ...

It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

Enodia Therapeutics SAS has raised €20.7 million ($25 million) in seed financing to advance its work developing novel small-molecule therapies for targeted protein degradation at the point of ...